Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178895 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178890 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL2182769 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL17746959 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178762 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178760 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178759 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178761 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178758 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178892 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1522 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352656-A1 | SYNTHETIC CATIONIC PEPTIDOMIMETICS, THEIR DERIVATIVES AND PREPARATION THEREOF ALONG WITH COMPOSITIONS FOR VARIOUS MEDICAL APPLICATIONS | PEPTOMER THERAPEUTICS PRIVATE LTD (IN) | 2025-11-20 | — | — | US | claimed |
| US-20250205372-A1 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-06-26 | — | — | US | claimed |
| CN-119912519-A | Double-target targeted polypeptide compound, preparation method and application | 中国人民解放军总医院第一医学中心 | 2025-05-02 | — | — | CN | claimed |
| EP-4525827-A1 | SYNTHETIC CATIONIC PEPTIDOMIMETICS, THEIR DERIVATIVES AND PREPARATION THEREOF ALONG WITH COMPOSITIONS FOR VARIOUS MEDICAL APPLICATIONS | Peptomer Therapeutics Private Limited (IN) | 2025-03-26 | — | — | EP | claimed |
| WO-2023209728-A1 | SYNTHETIC CATIONIC PEPTIDOMIMETICS, THEIR DERIVATIVES AND PREPARATION THEREOF ALONG WITH COMPOSITIONS FOR VARIOUS MEDICAL APPLICATIONS | PEPTOMER THERAPEUTICS PRIVATE LIMITED (IN) | 2023-11-02 | — | — | WO | claimed |
| CN-116903495-A | Preparation method of radioactive diagnostic drug ligand | 江苏华益科技有限公司 | 2023-10-20 | — | — | CN | claimed |
| WO-2023178313-A2 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-09-21 | — | — | WO | claimed |
| EP-1581486-B1 | METHOD FOR ASSAYING COMPOUNDS THAT DECREASE THE ACTIVITY OF POLY(ADP-RIBOSE)-POLYMERASE (PARP) | AVENTIS PHARMA INC (US) | 2009-07-29 | — | — | EP | claimed |
| EP-1581486-A4 | METHOD FOR ASSAYING COMPOUNDS THAT DECREASE THE ACTIVITY OF POLY(ADP-RIBOSE)-POLYMERASE (PARP) | AVENTIS PHARMA INC (US) | 2007-05-02 | — | — | EP | claimed |
| EP-1581486-A2 | METHOD FOR ASSAYING COMPOUNDS THAT DECREASE THE ACTIVITY OF POLY(ADP-RIBOSE)-POLYMERASE (PARP) | Aventis Pharmaceuticals, Inc. (US) | 2005-10-05 | — | — | EP | claimed |
| CN-1675543-A | Methods of detecting the ability of a compound or agent to decrease the activity of microsomal prostaglandin E synthase or hematopoietic prostaglandin D synthase | AVENTIS PHARMA INC (US) | 2005-09-28 | — | — | CN | claimed |
| EP-1543327-A2 | METHOD FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DECREASE THE ACTIVITY OF MICROSOMAL PROSTAGLANDIN E SYNTHASE OR HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Aventis Pharmaceuticals, Inc. (US) | 2005-06-22 | — | — | EP | claimed |
| EP-1506970-A1 | COMPOUNDS WHICH CAN BLOCK THE RESPONSE TO CHEMICAL SUBSTANCES OR THERMAL STIMULI OR MEDIATORS OF INFLAMMATION OF NOCICEPTORS, PRODUCTION METHOD THEREOF AND COMPOSITIONS CONTAINING SAME | Diverdrugs, S.L. (ES) | 2005-02-16 | — | — | EP | claimed |
| US-20040115710-A1 | Method for assaying compounds that decrease the activity of poly (ADP-ribose)-Polymerase (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2004-06-17 | — | — | US | claimed |
| US-20040082021-A1 | Method for assaying compounds or agents for ability to decrease the activity of microsomal prostaglandin E synthase or hematopoietic prostaglandin D synthase | AVENTIS PHARMACEUTICALS INC. | 2004-04-29 | — | — | US | claimed |
| WO-2004026820-A2 | METHOD FOR ASSAYING COMPOUNDS THAT DECREASE THE ACTIVITY OF POLY(ADP-RIBOSE)-POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2004-04-01 | — | — | WO | claimed |
| WO-2004016223-A2 | ASSAYING COMPOUNDS OR AGENTS FOR MICROSOMAL PROSTAGLANDIN E SYNTHASE OR HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE ACTIVITY | AVENTIS PHARMACEUTICALS INC. (US) | 2004-02-26 | — | — | WO | claimed |
| EP-4735047-A1 | PEGYLATED LINKERS AND USES THEREOF | Université de Tours (FR) | 2026-05-06 | — | — | EP | disclosed |
| WO-1989002439-A1 | NON-NUCLEOTIDE LINKING REAGENTS FOR NUCLEOTIDE PROBES | ML TECHNOLOGY VENTURES, L.P. (US) | 1989-03-23 | — | — | WO | disclosed |
| EP-0225807-A2 | Solution phase nucleic acid sandwich assay and polynucleotide probes useful therein | CHIRON CORPORATION (US) | 1987-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352656-A1 | SYNTHETIC CATIONIC PEPTIDOMIMETICS, THEIR DERIVATIVES AND PREPARATION THEREOF ALONG WITH COMPOSITIONS FOR VARIOUS MEDICAL APPLICATIONS | NOD2, NGLY1, CGAS | KMT2A 4744/4885HTT 211/4885EPHX2 2826/4885 |
| US-20250205372-A1 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | QPCT, SSTR5, SSTR4 | KMT2A 2814/4885HTT 321/4885EPHX2 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.